• Illumina posted Q2 2026 revenue of $1.16 billion, up 9.5%, driven by rising clinical demand and higher NovaSeq X consumables pull-through.
• Rest-of-world organic revenue grew 8.1%, beating guidance; sequencing gigabase output on connected high- and mid-throughput systems rose over 30%.
• NovaSeq X demand stayed elevated with over 95 placements; instrument revenue rose 31% to $125 million, supported by supply improvements.
• Non-GAAP gross margin was 68.2% despite higher freight and memory costs; non-GAAP EPS was $1.31, up 10%.
• Full-year guidance increased to $4.60-$4.64 billion revenue, rest-of-world organic growth above 5%, EPS of $5.30-$5.40 on mid-teens clinical growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Illumina Inc. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.